Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with ...

A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca is currently conducting a study titled ‘A Modular Phase ...

Combining the PARP1-selective inhibitor saruparib with an androgen receptor pathway inhibitor (ARPI) demonstrated promising efficacy and safety in patients with metastatic prostate cancer, according ...

Nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations do not receive ...

Prostate cancer begins in the small gland below the bladder that helps produce semen In advanced stages it can spread to other body parts most commonly the bones lymph nodes liver and lungs ...

Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

Higher BMI was associated with improved survival among patients with prostate cancer, especially those with metastatic disease.